Global health perspective in sarcomas and other rare cancers

V Florou, AG Nascimento, A Gulia… - American Society of …, 2018 - ascopubs.org
… , biosimilars are an alternative to biologic agents at a lower cost. A number of biosimilars
of and applications for biosimilars remain challenging, because biosimilars are not generics …

A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease

S Hwang, BH Lee, WS Kim, DS Kim, CK Cheon… - Medicine, 2022 - journals.lww.com
analysis was performed by linear and log-linear models. The PK of ISU303 were determined
by noncompartmental analysis … Once biosimilars are introduced, they must require close …

State, institutional entrepreneurship and the creation of the biopharmaceutical industry in a developing country

A Babaee, AN Mashayekhi… - Journal of Science and …, 2022 - emerald.com
… Some of the biosimilars produced in Iran are the first in the … analysis to ensure that the best
understanding was developed. The researchers stopped the iteration process between theory

Limitations of Protein Structure Prediction Algorithms in Therapeutic Protein Development

SK Niazi, Z Mariam, RZ Paracha - BioMedInformatics, 2024 - mdpi.com
… testing when these molecules are developed as biosimilars. We also studied modified structures
… Since it was demonstrated through previous studies and a comparative analysis in this …

Immunobiology of Cancer

N Verma, K Thapa, N Kanojia, P Chandel - Biosimilars for Cancer …, 2024 - Springer
notion. While a series of oncogenic events characterize the progression of cancer, the
characteristics … not all malignant cells share the characteristics of the disease. Another concern is …

Therapeutic antibody engineering and selection strategies

J Ministro, AM Manuel, J Goncalves - Current applications of …, 2020 - Springer
… and explored to obtain chosen characteristics of selected leading candidates such as high
… The development of biosimilar antibodies, which show a similar quality, efficacy, and safety …

[图书][B] Pharmaceutical competitive intelligence for the regulatory affairs professional

RA Huml - 2012 - books.google.com
… in connection with reviews or scholarly analysis or material … in Europe or start their biosimilars
projects (for products nearing … the process of natural evolution A field of computer science …

[图书][B] Endotoxin detection and control in pharma, limulus, and mammalian systems

KL Williams - 2019 - books.google.com
… [49] The legal basis for biosimilars in the EU is found in “Article 6 of … characterization methods,
the idea of an “identical copy” is not an acceptable one for pairing biologics and biosimilars

Personalized treatment for Crohn's disease: current approaches and future directions

JW Clinton, RK Cross - Clinical and Experimental …, 2023 - Taylor & Francis
… However, one systematic review and meta-analysis suggested mild superiority of …
Additionally, with the advent of biosimilars to both IFX and ADA, these agents may be the most cost-…

Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China

MY Zhang, J Li, H Hu, YT Wang - Health research policy and systems, 2015 - Springer
… above, we conducted the data analysis in two stages. First, … in terms of the seven dimensions
as defined above. Such an … are diversified and developed as biosimilar to the foreign …